News

UK’s Igniting Research Collaborations (IRC) program has awarded nearly $600,000 in pilot grants to support cross-college interdisciplinary research.

First Baptist Church Frankfort opened its doors to more than 500 individuals in the community to put an emphasis on their well-being.

Researchers at UK's Sanders-Brown Center on Aging are working to develop a pre-symptomatic disease diagnostic tool for Alzheimer’s disease.

Frankfort, Kentucky, has the nation’s second-highest prevalence of Alzheimer’s in Black adults. Yolanda Jackson, a clinician dietitian pursuing a Ph.D. in health communications, is working to develop accessible information about modifiable risk factors for the disease.

Thanks to medical advances, people with Down syndrome are living longer and fuller lives; however there is still much to learn about the Down syndrome brain.

Researchers at the University of Kentucky are studying how elements of our natural surroundings can be potential risk factors for Alzheimer’s disease — including chemicals widely used in plastics.

A team of researchers at the University of Kentucky has found that a drug used to treat multiple sclerosis (MS) is potentially effective as a therapy for Alzheimer’s disease.

Labor Day, September 4, WKYT-TV, is highlighting the world-class work going on at the University of Kentucky’s Sanders-Brown Center on Aging. The Lexington-based CBS affiliate will air a 30-minute special on their second station, The CW, at 6:30 p.m.

A recent study from the lab of the Sanders-Brown Center on Aging Director Linda Van Eldik, Ph.D., centers around the idea that various anti-inflammatory drugs could be effective treatments for Alzheimer’s disease.

The U.S. Food and Drug Administration (FDA) granted full approval to lecanemab, marketed as Leqembi, for the treatment of Alzheimer’s disease. The University of Kentucky’s Sanders-Brown Center on Aging has been working with this drug and others like it for more than a decade.